Citi lowered the firm’s price target on Exact Sciences to $80 from $100 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower peer multiples for the target drop, noting Cologuard posted a slight beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Exact Sciences Announces Board Member Retirement
- Exact Sciences CFO’s resume ‘impressive,’ says William Blair
- Exact Sciences Appoints Aaron Bloomer as New CFO